Stig Östlund

lördag, juni 02, 2012

NEJM June 2

Anti-PD-1 Antibody in Cancer
original article Online First
Releasing T cells from inhibitory control has been a strategy exploited by the anti–CTLA-4 antibody ipilimumab. Now an antibody against a second checkpoint molecule, programmed death 1 (PD-1), has also shown activity against cancers, including non–small-cell lung cancer.
  • Comments

editorial

Bloggarkiv